1
|
Rodon N, Trias I, Verdú M, Calvo M, Banus JM, Puig X. Correlation of mRNA-PCA3 urine levels with the new grading system in prostate cancer. REVISTA ESPAÑOLA DE PATOLOGÍA : PUBLICACIÓN OFICIAL DE LA SOCIEDAD ESPAÑOLA DE ANATOMÍA PATOLÓGICA Y DE LA SOCIEDAD ESPAÑOLA DE CITOLOGÍA 2018; 52:20-26. [PMID: 30583827 DOI: 10.1016/j.patol.2018.04.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Revised: 04/18/2018] [Accepted: 04/22/2018] [Indexed: 10/28/2022]
Abstract
PURPOSE To evaluate the PCA3 (Prostate Cancer 3 gene) as a tool to improve prostate cancer (PCa) screening and its capability to predict PCa aggressiveness. PATIENTS AND METHODS A retrospective study with data from consecutive patients with suspected PCa seen in the urology department between November 2009 and April 2016 and who were candidates for prostate biopsy. A total of 1038 urine samples were tested in our laboratory with a kit that generated a PCA3 score (s-PCA3). A prostate biopsy was recommended only in those patients with s-PCA3≥35. Associations between variables were analyzed using the R software. RESULTS In patients with a positive s-PCA3 (44.5%), a subsequent biopsy was recommended. Of a total of 151 biopsies studied, 56.3% yielded a diagnosis of PCa. The probability of a positive biopsy increased as the s-PCA3 increased (p=0.041). The percentage of affected cylinders increased as the s-PCA3 increased (p=0.015). A statistically significant relationship was observed between s-PCA3 and both the Gleason score and the Grade Group (p=0.001 and 0.008, respectively). The best log-linear models and a logistic model confirmed the relationships shown previously with Fisher's exact tests. CONCLUSIONS S-PCA3 may serve as an additional marker to reduce the indication for biopsies and avoid overdiagnosis and overtreatment of patients with suspected PCa. The prognostic significance of s-PCA3 was confirmed, as it was associated with tumor volume and Gleason score. Importantly, to our knowledge this is the first time that an association has been demonstrated between s-PCA3 and the new Grade Group.
Collapse
Affiliation(s)
- Natalia Rodon
- BIOPAT, Biopatologia Molecular SL, Grup Assistència, Barcelona, Spain.
| | - Isabel Trias
- BIOPAT, Biopatologia Molecular SL, Grup Assistència, Barcelona, Spain; HISTOPAT Laboratoris, Barcelona, Spain; Hospital de Barcelona, SCIAS, Grup Assistència, Barcelona, Spain
| | - Montse Verdú
- BIOPAT, Biopatologia Molecular SL, Grup Assistència, Barcelona, Spain; HISTOPAT Laboratoris, Barcelona, Spain
| | - Miquel Calvo
- Department of Statistics, Faculty of Biology, Universitat de Barcelona, Barcelona, Spain
| | - Josep Mª Banus
- ICUN, Institut Català d'Urologia i Nefrologia, Barcelona, Spain
| | - Xavier Puig
- BIOPAT, Biopatologia Molecular SL, Grup Assistència, Barcelona, Spain; HISTOPAT Laboratoris, Barcelona, Spain; Hospital de Barcelona, SCIAS, Grup Assistència, Barcelona, Spain
| |
Collapse
|
2
|
Bremner KE, Chong CAKY, Tomlinson G, Alibhai SMH, Krahn MD. A Review and Meta-Analysis of Prostate Cancer Utilities. Med Decis Making 2016; 27:288-98. [PMID: 17502448 DOI: 10.1177/0272989x07300604] [Citation(s) in RCA: 83] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background. Health-related quality of life is a key issue in prostate cancer (PC) management. The authors summarized published utilities for common health-related quality of life outcomes of PC and determined how methodological factors affect them. Methods. In their systematic review, the authors identified 23 articles in English, providing 173 unique utilities for PC health states, each obtained from 2 to 422 respondents. Data were pooled using linear mixed-effects modeling with utilities clustered within the study, weighted by the number of respondents divided by the variance of each utility. Results. In the base model, the estimated utility of the reference case (scenario of a metastatic PC patient with severe sexual symptoms, rated by non-PC patients using time tradeoff) was 0.76. Disease stage, symptom type and severity, source of utility, and scaling method were associated with utility differences of 0.10 to 0.32 (P < 0.05). Utilities from PC patients rating their own health were 0.14 higher than those from the reference case, but utilities from PC patients rating scenarios were lowest. Time tradeoff yielded the highest utilities. Computer administration yielded lower utilities than personal interview (P = 0.02). Neither the scale's high anchor nor study purpose had significant effects on utilities. Conclusions. This study provides pooled utility estimates for common PC health states and describes how clinical and methodological factors can significantly affect these values. When possible, utility estimates for a modeling application should be derived similarly. Formal data synthesis methods might be useful to researchers integrating utility data from heterogeneous sources. Further exploration of these methods for this purpose is warranted.
Collapse
Affiliation(s)
- Karen E Bremner
- Toronto General Research Institute University Health Network, Canada.
| | | | | | | | | |
Collapse
|
3
|
Elabbady A, Eid A, Fahmy A, Kotb AF. Pattern of prostate cancer presentation among the Egyptian population: A study in a single tertiary care center. Cent European J Urol 2014; 67:351-6. [PMID: 25667753 PMCID: PMC4310882 DOI: 10.5173/ceju.2014.04.art7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2014] [Revised: 05/01/2014] [Accepted: 06/23/2014] [Indexed: 12/03/2022] Open
Abstract
INTRODUCTION Prostate cancer is a common health problem that in the majority of cases starts to develop at the age of 50 years, reaching its peak at 60-70 years of age. A variation in its incidence and prevalence exists between western, Asian and Arabic populations. The aim of our work was to report the pattern of prostate cancer presentation in Alexandria University that as a tertiary referral center provides care for uro-oncology cases. MATERIAL AND METHODS Data collection for all patients diagnosed with prostate cancer at Alexandria University in Egypt through the year 2012 was done. RESULTS The mean age of the patients was 67. Mean serum total PSA, prostate volume and PSAd were 149 ng/ml, 63 grams and 3.1 ng/ml/gm respectively. 25% of patients were asymptomatic diagnosed accidentally during screening for prostate cancer. The remaining group was presenting with LUTS, including 23 patients who presented initially with back pain. CONCLUSIONS Egyptian men with prostate cancer have a markedly high PSA density and Gleason grade at diagnosis.
Collapse
Affiliation(s)
- Ahmed Elabbady
- University of Alexandria, Faculty of Medicine, Department of Urology, Alexandria, Egypt
| | - Ahmed Eid
- University of Alexandria, Faculty of Medicine, Department of Urology, Alexandria, Egypt
| | - Ahmed Fahmy
- University of Alexandria, Faculty of Medicine, Department of Urology, Alexandria, Egypt
| | - Ahmed Fouad Kotb
- University of Alexandria, Faculty of Medicine, Department of Urology, Alexandria, Egypt
| |
Collapse
|
4
|
Al-Abdin OZ, Rabah DM, Badr G, Kotb A, Aprikian A. Differences in prostate cancer detection between Canadian and Saudi populations. Braz J Med Biol Res 2013; 46:539-45. [PMID: 23802226 PMCID: PMC3854441 DOI: 10.1590/1414-431x20132757] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2012] [Accepted: 03/20/2013] [Indexed: 11/22/2022] Open
Abstract
Few studies have addressed racial differences in prostate cancer (PCa) detection
between Western and Arabian countries, although PCa has a significantly lower
prevalence in Arabic populations compared to Western populations. Therefore, an
explanation of this difference is lacking. Serum prostate-specific antigen (PSA)
is a valuable marker used to select patients who should undergo prostate
biopsies, although the manner in which it is used may require adjustments based
on the ethnic population in question. We investigated racial differences in the
PCa detection rate between Canadian and Saudi populations. A retrospective
analysis was performed of data collected prospectively over 5 consecutive years
in urology clinics at the McGill University Health Center (MUHC) and King Saud
University Hospital (KSUH). Men who had high (>4'ng/mL) or rising PSA levels
and a negative digital rectal examination were eligible. A total of 1403
Canadian and 414 Saudi patients were evaluated for the study; 717 and 158 men,
median age 64 and 68 years, were included in the MUHC and KSUH cohorts,
respectively, P<0.0001). Median serum PSA, prostate volume, and PSA density
values were 6.1'ng/mL, 47.3 g, and 0.12'ng·mL−1·g−1,
respectively, for MUHC patients and 5.2'ng/mL, 64.5'g, and
0.08'ng·mL−1·g−1, respectively, for KSUH patients
(P<0.0001, t-test followed by one-way ANOVA). In addition, the KSUH group had
a significantly lower PCa detection rate among patients younger than 60 years of
age and with PSA values <10'ng/mL.
Collapse
Affiliation(s)
- O Z Al-Abdin
- King Saud University, Princess Al-Johara Al-Ibrahim Center for Cancer Research, Prostate Cancer Research Chair, College of Medicine, Prostate Cancer Research Chair, Riyadh, Saudi Arabia
| | | | | | | | | |
Collapse
|
5
|
Kamaleshwaran KK, Mittal BR, Harisankar CNB, Bhattacharya A, Singh SK, Mandal AK. Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy. Indian J Nucl Med 2013; 27:81-4. [PMID: 23723577 PMCID: PMC3665151 DOI: 10.4103/0972-3919.110683] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Introduction: Radionuclide bone scan (BS) used to be the investigation of choice for detecting osseous metastases in prostate cancer. Now, with the availability serum prostate specific antigen (PSA) testing, clinicians do have a timely, cost-effective method to determine those patients who are highly unlikely to have osseous metastases. We determine the utility of PSA for predicting the presence of skeletal metastasis on BSs in prostate cancer patients. Materials and Methods: Retrospective analysis of medical records of 322 consecutive prostate cancers patients subjected to BS during the last 3 years was done. 52 cases were excluded due to following reasons: Serum PSA not available, hormonal or other therapy given prior to serum PSA measurement, and/or BS, and symptomatic for bone metastasis. In remaining 270 cases, PSA value and BS were evaluated. BS was performed with Tc99m methylene diphosphonate (MDP) as per the standard protocol. Results: BS was found to be positive in 153/270 (56%) and negative in 117 (46%) patients. Of the 153 positive cases, 108 (70%) had serum PSA > 100 ng/ml, 42 (28%) had PSA of 20-100 ng/ml and only 3 (2%) had PSA < 20 ng/ml. All the patients with PSA > 100 ng/ml had multiple skeletal metastasis. Of the 117 negative cases, 110 (94%) had a PSA < 20 ng/ml, 5 had between 20 and 100 ng/ml and only 2 (1.8%) had PSA > 100 ng/ml. Of the 113 patients with serum PSA < 20 ng/ml, 110 (97.4%) did not show any bony metastasis. 150/157 (95.5%) patients with PSA > 20 ng/ml had bone metastasis. Using this criterion, 110 (40.7%) scans would have been omitted. Conclusions: Serum PSA < 20 ng/ml have high predictive value in ruling out skeletal metastasis. Our data are in corroboration with results from previous studies that BS should be performed only if PSA > 20 ng/ml. Using this cut-off, unnecessary investigation can be avoided. Avoiding BS in this group of patients would translate into a significant cost-saving and reduction in their psychological and physical burden.
Collapse
|
6
|
Abstract
BACKGROUND Any form of screening aims to reduce disease-specific and overall mortality, and to improve a person's future quality of life. Screening for prostate cancer has generated considerable debate within the medical and broader community, as demonstrated by the varying recommendations made by medical organizations and governed by national policies. To better inform individual patient decision-making and health policy decisions, we need to consider the entire body of data from randomised controlled trials (RCTs) on prostate cancer screening summarised in a systematic review. In 2006, our Cochrane review identified insufficient evidence to either support or refute the use of routine mass, selective, or opportunistic screening for prostate cancer. An update of the review in 2010 included three additional trials. Meta-analysis of the five studies included in the 2010 review concluded that screening did not significantly reduce prostate cancer-specific mortality. In the past two years, several updates to studies included in the 2010 review have been published thereby providing the rationale for this update of the 2010 systematic review. OBJECTIVES To determine whether screening for prostate cancer reduces prostate cancer-specific mortality or all-cause mortality and to assess its impact on quality of life and adverse events. SEARCH METHODS An updated search of electronic databases (PROSTATE register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CANCERLIT, and the NHS EED) was performed, in addition to handsearching of specific journals and bibliographies, in an effort to identify both published and unpublished trials. SELECTION CRITERIA All RCTs of screening versus no screening for prostate cancer were eligible for inclusion in this review. DATA COLLECTION AND ANALYSIS The original search (2006) identified 99 potentially relevant articles that were selected for full-text review. From these citations, two RCTs were identified as meeting the inclusion criteria. The search for the 2010 version of the review identified a further 106 potentially relevant articles, from which three new RCTs were included in the review. A total of 31 articles were retrieved for full-text examination based on the updated search in 2012. Updated data on three studies were included in this review. Data from the trials were independently extracted by two authors. MAIN RESULTS Five RCTs with a total of 341,342 participants were included in this review. All involved prostate-specific antigen (PSA) testing, with or without digital rectal examination (DRE), though the interval and threshold for further evaluation varied across trials. The age of participants ranged from 45 to 80 years and duration of follow-up from 7 to 20 years. Our meta-analysis of the five included studies indicated no statistically significant difference in prostate cancer-specific mortality between men randomised to the screening and control groups (risk ratio (RR) 1.00, 95% confidence interval (CI) 0.86 to 1.17). The methodological quality of three of the studies was assessed as posing a high risk of bias. The European Randomized Study of Screening for Prostate Cancer (ERSPC) and the US Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial were assessed as posing a low risk of bias, but provided contradicting results. The ERSPC study reported a significant reduction in prostate cancer-specific mortality (RR 0.84, 95% CI 0.73 to 0.95), whilst the PLCO study concluded no significant benefit (RR 1.15, 95% CI 0.86 to 1.54). The ERSPC was the only study of the five included in this review that reported a significant reduction in prostate cancer-specific mortality, in a pre-specified subgroup of men aged 55 to 69 years of age. Sensitivity analysis for overall risk of bias indicated no significant difference in prostate cancer-specific mortality when referring to the meta analysis of only the ERSPC and PLCO trial data (RR 0.96, 95% CI 0.70 to 1.30). Subgroup analyses indicated that prostate cancer-specific mortality was not affected by the age at which participants were screened. Meta-analysis of four studies investigating all-cause mortality did not determine any significant differences between men randomised to screening or control (RR 1.00, 95% CI 0.96 to 1.03). A diagnosis of prostate cancer was significantly greater in men randomised to screening compared to those randomised to control (RR 1.30, 95% CI 1.02 to 1.65). Localised prostate cancer was more commonly diagnosed in men randomised to screening (RR 1.79, 95% CI 1.19 to 2.70), whilst the proportion of men diagnosed with advanced prostate cancer was significantly lower in the screening group compared to the men serving as controls (RR 0.80, 95% CI 0.73 to 0.87). Screening resulted in a range of harms that can be considered minor to major in severity and duration. Common minor harms from screening include bleeding, bruising and short-term anxiety. Common major harms include overdiagnosis and overtreatment, including infection, blood loss requiring transfusion, pneumonia, erectile dysfunction, and incontinence. Harms of screening included false-positive results for the PSA test and overdiagnosis (up to 50% in the ERSPC study). Adverse events associated with transrectal ultrasound (TRUS)-guided biopsies included infection, bleeding and pain. No deaths were attributed to any biopsy procedure. None of the studies provided detailed assessment of the effect of screening on quality of life or provided a comprehensive assessment of resource utilization associated with screening (although preliminary analyses were reported). AUTHORS' CONCLUSIONS Prostate cancer screening did not significantly decrease prostate cancer-specific mortality in a combined meta-analysis of five RCTs. Only one study (ERSPC) reported a 21% significant reduction of prostate cancer-specific mortality in a pre-specified subgroup of men aged 55 to 69 years. Pooled data currently demonstrates no significant reduction in prostate cancer-specific and overall mortality. Harms associated with PSA-based screening and subsequent diagnostic evaluations are frequent, and moderate in severity. Overdiagnosis and overtreatment are common and are associated with treatment-related harms. Men should be informed of this and the demonstrated adverse effects when they are deciding whether or not to undertake screening for prostate cancer. Any reduction in prostate cancer-specific mortality may take up to 10 years to accrue; therefore, men who have a life expectancy less than 10 to 15 years should be informed that screening for prostate cancer is unlikely to be beneficial. No studies examined the independent role of screening by DRE.
Collapse
Affiliation(s)
- Dragan Ilic
- Department of Epidemiology&PreventiveMedicine, School of PublicHealth&PreventiveMedicine,MonashUniversity,Melbourne,Australia.
| | | | | | | |
Collapse
|
7
|
Underwood DJ, Zhang J, Denton BT, Shah ND, Inman BA. Simulation optimization of PSA-threshold based prostate cancer screening policies. Health Care Manag Sci 2012; 15:293-309. [PMID: 22302420 DOI: 10.1007/s10729-012-9195-x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2011] [Accepted: 01/23/2012] [Indexed: 10/14/2022]
Abstract
We describe a simulation optimization method to design PSA screening policies based on expected quality adjusted life years (QALYs). Our method integrates a simulation model in a genetic algorithm which uses a probabilistic method for selection of the best policy. We present computational results about the efficiency of our algorithm. The best policy generated by our algorithm is compared to previously recommended screening policies. Using the policies determined by our model, we present evidence that patients should be screened more aggressively but for a shorter length of time than previously published guidelines recommended.
Collapse
Affiliation(s)
- Daniel J Underwood
- Edward P. Fitts Department of Industrial & Systems Engineering, North Carolina State University, Raleigh, NC 27695, USA.
| | | | | | | | | |
Collapse
|
8
|
Tomlinson G, Bremner KE, Ritvo P, Naglie G, Krahn MD. Development and validation of a utility weighting function for the patient-oriented prostate utility scale (PORPUS). Med Decis Making 2011; 32:11-30. [PMID: 21653804 DOI: 10.1177/0272989x11407203] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND Previously, we developed a prostate cancer (PC)-specific health state classification system, the Patient Oriented Prostate Utility Scale (PORPUS). In this study, we developed a scoring system to allow indirect calculation of utilities from the PORPUS. METHODS We interviewed 234 PC outpatients, including those with newly diagnosed and metastatic disease, to obtain rating scale (RS) values on 4 to 6 levels of each of the 10 attributes of the PORPUS, and on 10 corner states (worst level on 1 attribute, best on 9). Patients also completed standard gamble (SG) and RS tasks on 4 multiattribute states (impotence and pain corner states, mild and severe PC symptoms). We used the RS and SG scores for multiattribute states to determine a risk aversion function for mapping values to utilities. We then tested 15 different strategies to estimate the multiattribute utility function (MAUF), using the single attribute disutilities for each level of the 10 PORPUS attributes, and the disutilities for the corner states. The root mean squared error (RMSE) of prediction of the SG on the 4 multiattribute states was used to identify the optimal strategy and scoring system. RESULTS The optimal strategy gave an RMSE of 0.06. Comparison of mean MAUF-predicted utilities to directly elicited SG utilities for the 2 multiattribute states from patients in 2 previously published studies (n = 248 and n = 141) supported the validity of the MAUF. CONCLUSIONS The scoring system together with the PORPUS comprise an indirect utility instrument, the PORPUS-U, which can be used in clinical and research settings.
Collapse
Affiliation(s)
- George Tomlinson
- Department of Medicine and Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada (GT, GN, MDK),Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada (GT, KEB, MDK),Toronto Health Economics and Technology Assessment Collaborative (THETA), Toronto, Ontario, Canada (GT, KEB, MDK),Department of Public Health Sciences, University of Toronto, Toronto, Ontario, Canada (GT)
| | - Karen E Bremner
- Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada (GT, KEB, MDK),Toronto Health Economics and Technology Assessment Collaborative (THETA), Toronto, Ontario, Canada (GT, KEB, MDK)
| | - Paul Ritvo
- Department of Psychology, University of Toronto, and Cancer Care Ontario, Toronto, Ontario, Canada (PR)
| | - Gary Naglie
- Department of Medicine and Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada (GT, GN, MDK),Baycrest Centre, Toronto, Ontario, Canada (GN)
| | - Murray D Krahn
- Department of Medicine and Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada (GT, GN, MDK),Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada (MDK),Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada (GT, KEB, MDK),Toronto Health Economics and Technology Assessment Collaborative (THETA), Toronto, Ontario, Canada (GT, KEB, MDK)
| |
Collapse
|
9
|
CD147 expression indicates unfavourable prognosis in prostate cancer. Pathol Oncol Res 2010; 15:369-74. [PMID: 19048397 DOI: 10.1007/s12253-008-9131-z] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/25/2008] [Accepted: 11/11/2008] [Indexed: 10/21/2022]
Abstract
Extracellular matrix metalloproteinase inducer (EMMPRIN, also named as CD147) is a multifunctional membrane glycoprotein over-expressed in many kinds of human solid tumors. It has been demonstrated to be involved in tumor invasion and angiogenesis. The aim of this study was to analyze the clinicopathological characteristics of the expression of CD147 in human prostate cancer (PCa), and to evaluate its clinical significance in the histologic classification and prognosis of PCa. CD147 protein expression in paraffin-embedded specimens gathered from 62 cases of PCa and 30 cases of benign prostatic hyperplasia (BPH) were detected by the method of immunohistochemistry. The association of CD147 protein expression with the clinicopathological characteristics and with the prognosis of PCa was subsequently assessed. CD147 expression were positively expressed in 51/62 (82.3%) of PCa and 4/30 (13.3%) of BPH cases, respectively. The positive expression rate of CD147 in PCa tissues was significantly higher than that in BPH. The positive expression of CD147 was dramatically associated with TNM grade (p < 0.001), the depth of the prostatic wall invasion (p = 0.008), GLEASON Score (p = 0.001) and Histologic grade (p = 0.001). The patients with CD147 expression were associated with a poor prognosis of PCa (p = 0.01) and the survival rate of the patients with a strong positive expression of CD147 was the lowest (p = 0.01). The results suggest that the expression of CD147 may be an important feature of PCa and the detection of its expression may benefit us in the prediction of the prognosis of PCa.
Collapse
|
10
|
Gjengstø P, Eide J, Frugård J, Bakke A, Høisaeter PA. The potentially curable prostate cancer patient and the pathways leading to diagnosis and treatment. ACTA ACUST UNITED AC 2009; 38:15-8. [PMID: 15204421 DOI: 10.1080/00365590310019990] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
OBJECTIVE Potentially curable prostate cancer is a diagnostic challenge for the general practitioner (GP). In a defined catchment area we wanted to discover why patients consulted their GPs and the reasons for their referral to the urologist. MATERIAL AND METHODS Patients remitted to our "early prostate cancer clinic" with suspected potentially curable prostate cancer between January 1997 and December 2000 were included in the study. Patient information was registered according to a prospectively designed protocol. RESULTS Of the 872 patients examined, prostate cancer was diagnosed in 41.3% (360/872). Median age was 63.1 years and median total prostate-specific antigen (PSA) level was 8.6 microg/l. The main reason for referral to a urologist was elevated PSA alone. However, the majority of the patients had no urological symptoms when they consulted their GP. As no local or national screening recommendations existed, we believe that opportunistic PSA screening has been common. CONCLUSIONS The most important reason for referring patients to our specialist clinic was elevated PSA, often detected by means of opportunistic PSA screening. This study shows the effect of PSA testing in real-life practice.
Collapse
Affiliation(s)
- Peder Gjengstø
- Section of Urology, Department of Surgery, The Gade Institute, Haukeland University Hospital, Bergen, Norway.
| | | | | | | | | |
Collapse
|
11
|
Bi X, He H, Ye Y, Dai Q, Han Z, Liang Y, Zhong W. Association of TMPRSS2 and KLK11 gene expression levels with clinical progression of human prostate cancer. Med Oncol 2009; 27:145-51. [PMID: 19242826 DOI: 10.1007/s12032-009-9185-0] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2008] [Accepted: 02/09/2009] [Indexed: 10/21/2022]
Abstract
AIM The aim of this study was to analyze the clinicopathological characteristics of TMPRSS2 and KLK11 gene expression levels in human prostate cancer (PCa), and to evaluate their clinical significance in the progression of PCa. METHODS The expression of prostate-type and brain-type isoforms of KLK11 gene, and TMPRSS2 gene was analyzed by quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) in 63 PCa tissues. The correlation of TMPRSS2 and KLK11 gene expression with the clinicopathological characteristics and with the prognosis of PCa was subsequently assessed. RESULTS The mean values of TMPRSS2 (3.91 +/- 0.78 in PCa vs. 0.26 +/- 0.04 in normal prostate tissues) and both isoforms of KLK11 (prostate-type: 3.63 +/- 0.42 in PCa vs. 0.49 +/- 0.07 in normal prostate tissues; brain-type: 3.11 +/- 0.30 in PCa vs. 0.46 +/- 0.05 in normal prostate tissues) were significantly higher in cancer tissues compared with their normal counterparts. We found a significant positive correlation between TMPRSS2 expression and tumor stage (P = 0.02), Gleason score (P = 0.008), and tumor grade (P = 0.016). Regarding prostate-type KLK11, we identified a significant association between lower expression and higher tumor stage (P = 0.009), Gleason score (P = 0.01), and tumor grade (P = 0.006). No such association was seen with the brain-type isoform. The survival rate of the patients with TMPRSS2-high/KLK11-low expression was lowest (P = 0.003). CONCLUSION The results suggest that the up-regulation of TMPRSS2 gene and the down-regulation of KLK11 gene in advanced and more aggressive tumors may open the feasibility of being used as biomarkers distinguishing the tumor aggressiveness as well as novel prognostic indicators for PCa.
Collapse
Affiliation(s)
- Xuecheng Bi
- Department of Urology, Southern Medical University, Guangzhou, China
| | | | | | | | | | | | | |
Collapse
|
12
|
Pal RP, Thiruudaian T, Khan MA. When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer? Asian J Androl 2008; 10:890-5. [DOI: 10.1111/j.1745-7262.2008.00427.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
13
|
Clements A, Watson E, Rai T, Bukach C, Shine B, Austoker J. The PSA testing dilemma: GPs' reports of consultations with asymptomatic men: a qualitative study. BMC FAMILY PRACTICE 2007; 8:35. [PMID: 17593306 PMCID: PMC1925086 DOI: 10.1186/1471-2296-8-35] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 02/13/2007] [Accepted: 06/25/2007] [Indexed: 02/05/2023]
Abstract
BACKGROUND The National Health Service Prostate Cancer Risk Management Programme (PCRMP) has recommended that screening for prostate cancer is available for asymptomatic men, on the understanding that they have been provided with full and balanced information about the advantages and limitations of the prostate-specific antigen (PSA) test. Guidance has been distributed to all GPs in England and Wales to assist in the provision of information to men. This study aimed to elicit GPs' accounts of their discussions with asymptomatic men who consult with concerns about prostate cancer in order to identify the degree to which the PCRMP guidance was reflected in these consultations. METHODS Qualitative interview study. Semi-structured telephone interviews with 21 GPs from 18 GP practices in Oxfordshire. RESULTS All GPs reported undertaking some discussion with asymptomatic men about the PSA test. They described focussing most of the discussion on the false-positive and false-negative rates of the test, and the risks associated with a prostate biopsy. They reported less discussion of the potential for diagnosing indolent cancers, the dilemmas regarding treatment options for localised prostate cancer and the potential benefits of testing. Considerable variation existed between GPs in their accounts of the degree of detail given, and GP's presentation of information appeared to be affected by their personal views of the PSA test. CONCLUSION The GPs in this study appear to recognise the importance of discussions regarding PSA testing; however, a full and balanced picture of the associated advantages and limitations does not seem to be consistently conveyed. Factors specific to PSA testing which appeared to have an impact on the GPs' discussions were the GP's personal opinions of the PSA test, and the need to counter men's primarily positive views of the benefits of PSA testing. Awareness of the impact of their views on the consultations may help GPs give men a more balanced presentation of the benefits and limitations of the PSA test.
Collapse
Affiliation(s)
- Alison Clements
- Cancer Research UK Primary Care Education Research Group, Department of Primary Health Care, University of Oxford. Rosemary Rue Building, Old Road Campus, Headington, Oxford, OX3 7LF, UK
| | - Eila Watson
- Cancer Research UK Primary Care Education Research Group, Department of Primary Health Care, University of Oxford. Rosemary Rue Building, Old Road Campus, Headington, Oxford, OX3 7LF, UK
| | - Tanvi Rai
- Cancer Research UK Primary Care Education Research Group, Department of Primary Health Care, University of Oxford. Rosemary Rue Building, Old Road Campus, Headington, Oxford, OX3 7LF, UK
| | - Colleen Bukach
- Cancer Research UK Primary Care Education Research Group, Department of Primary Health Care, University of Oxford. Rosemary Rue Building, Old Road Campus, Headington, Oxford, OX3 7LF, UK
| | - Brian Shine
- Department of Clinical Biochemistry, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK
| | - Joan Austoker
- Cancer Research UK Primary Care Education Research Group, Department of Primary Health Care, University of Oxford. Rosemary Rue Building, Old Road Campus, Headington, Oxford, OX3 7LF, UK
| |
Collapse
|
14
|
Abstract
Prostate cancer incurs a substantial incidence and mortality burden, similarly to breast cancer, and it ranks among the top ten specific causes of death in the United States. It is inherent as we maximize the detection of early prostate cancer that we increase the detection of both nonaggressive (slow growing) and aggressive (faster growing) prostate cancers. The evidence clearly supports the use of PSA screening in conjunction with DRE as a means of early detection of prostate cancer. Widespread implementation of prostate cancer screening in the United States has led to the phenomenon of stage migration with more cancers being detected at a lower stage. Such a trend has decreased the incidence of metastatic disease at diagnosis and paralleled the decrease of the mortality rate from prostate cancer. Our understanding of the natural history of prostate cancer is progressing over time, but the question of its length is unanswerable. The relatively long doubling time (on average) of early prostate cancer of 3 to 4 years or more indicates a relatively good prognosis for many men with this disease, even without early detection and treatment. Unfortunately, the poor specificity of the PSA test in men with benign prostatic hyperplasia (BPH) leads to high rates of prostate biopsy and attendant illnesses and costs. Early detection is more apt to detect a slow-growing prostate cancer than a faster growing cancer that is associated with a more rapid course of progression to metastatic disease. Hence, the launching of mass screening programs for the early detection of prostate cancer is premature. However, in the absence of solid evidence of benefit, one reasonable approach to screening at the individual level is to involve the patient in decisions about whether or not to perform a PSA test. Thus, "offering" PSA testing must be accompanied by informed discussion within the context of an ongoing patient-physician relationship. This is to be distinguished from the use of PSA testing for the purpose of "mass screening." Concepts that must be explored with the patient include: 1. The long-term ramifications of screening 2. The relatively high probability of further evaluation and biopsy with positive results 3. Potentially difficult decisions that may arise about using treatments that are associated with considerable morbidity and uncertain benefits (at the time) if cancer is discovered We should identify a future path that is evidence-based, focused on the issues that make a difference to patients, and results in better and longer lives of those with the disease and those who are at risk of getting it. If that path leads to treating fewer patients in the future, even if sometimes more aggressively, we should pursue it definitely and consequently.
Collapse
Affiliation(s)
- P Tenke
- Department of Urology, Jahn Ferenc South-Pest Hospital, Budapest, Hungary
| | | | | | | |
Collapse
|
15
|
Affiliation(s)
- Jenny Donovan
- Department of Social Medicine, University of Bristol, UK
| | | |
Collapse
|
16
|
Anim JT, Kehinde EO, Sheikh MA, Prasad A, Mojiminiyi OA, Ali Y, Al-Awadi KA. Serum prostate-specific antigen levels in Middle Eastern men with subclinical prostatitis. Med Princ Pract 2007; 16:53-8. [PMID: 17159365 DOI: 10.1159/000096141] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2005] [Accepted: 04/04/2006] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVE To investigate the influence of subclinical or histologically diagnosed prostatitis on serum prostate-specific antigen (PSA) in patients investigated for prostatic disease in Kuwait. MATERIALS AND METHODS Serum PSA was assayed in patients investigated for prostatic disease in Mubarak Al-Kabeer Hospital, Kuwait, between December 2002 and December 2004. These included patients undergoing transrectal ultrasound with needle biopsy of the prostate gland and those who were treated with transurethral resection of the prostate or retropubic prostatectomy. The tissue was evaluated for prostatitis as well as the underlying disease, and the type and severity of prostatitis were compared with levels of serum PSA. RESULTS Of the 331 tissue specimens, 18 (5.4%) did not show prostatitis, while 233 (70.4%) with benign prostate and 80 (24.2%) with malignant prostate disease showed prostatitis. Of 270 men with known serum PSA levels, 198 and 72 had benign and malignant prostate disease, respectively. Of the 198, 77 (41%) with benign prostate disease and prostatitis and of the 72, 52 (76%) with malignant prostate disease and prostatitis had serum PSA levels >10 ng/ml. CONCLUSION The data showed that although raised serum PSA is more commonly associated with prostate cancer, subclinical prostatitis is a significant source of high serum PSA in over 40% of men in Kuwait. That local factors may obscure the usefulness of serum PSA as a screening tool suggests the need for a locally applicable paradigm to identify prostate cancer.
Collapse
Affiliation(s)
- J T Anim
- Department of Pathology, Faculty of Medicine, Kuwait University, Kuwait.
| | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
BACKGROUND Any form of screening aims to reduce mortality and increase a person's quality of life. Screening for prostate cancer has generated considerable debate within the medical community, as demonstrated by the varying recommendations made by medical organizations and governed by national policies. Much of this debate is due to the limited availability of high quality research and the influence of false-positive or false-negative results generated by use of the diagnostic techniques such as the digital rectal examination (DRE) and prostate specific antigen (PSA) blood test. OBJECTIVES To determine whether screening for prostate cancer reduces prostate cancer mortality and has an impact on quality of life. SEARCH STRATEGY Electronic databases (PROSTATE register, CENTRAL the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CANCERLIT and the NHS EED) were searched electronically in addition to hand searching of specific journals and bibliographies in an effort to identify both published and unpublished trials. SELECTION CRITERIA All randomised controlled trials of screening versus no screening or routine care for prostate cancer were eligible for inclusion in this review. DATA COLLECTION AND ANALYSIS The search identified 99 potentially relevant articles that were selected for full text review. From these 99 citations, two randomised controlled trials were identified as meeting the review's inclusion criteria. Data from the trials were independently extracted by two authors. MAIN RESULTS Two randomised controlled trials with a total of 55,512 participants were included; however, both trials had methodological weaknesses. Re-analysis using intention-to-screen and meta-analysis of results from the two randomised controlled trials indicated no statistically significant difference in prostate cancer mortality between men randomised for prostate cancer screening and controls (RR 1.01, 95% CI: 0.80-1.29). Neither study assessed the effect of prostate cancer screening on quality of life, all-cause mortality or cost effectiveness. AUTHORS' CONCLUSIONS Given that only two randomised controlled trials were included, and the high risk of bias of both trials, there is insufficient evidence to either support or refute the routine use of mass, selective or opportunistic screening compared to no screening for reducing prostate cancer mortality. Currently, no robust evidence from randomised controlled trials is available regarding the impact of screening on quality of life, harms of screening, or its economic value. Results from two ongoing large scale multicentre randomised controlled trials that will be available in the next several years are required to make evidence-based decisions regarding prostate cancer screening.
Collapse
Affiliation(s)
- D Ilic
- Monash University, Australasian Cochrane Centre, Monash Institute of Health Services Research, Locked Bag 29, Monash Medical Centre, Clayton, Victoria, Australia 3168.
| | | | | | | |
Collapse
|
18
|
Raja J, Ramachandran N, Munneke G, Patel U. Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. Clin Radiol 2006; 61:142-53. [PMID: 16439219 DOI: 10.1016/j.crad.2005.10.002] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2005] [Revised: 09/11/2005] [Accepted: 10/07/2005] [Indexed: 11/18/2022]
Abstract
In contemporary practice, most prostate cancers are either invisible on ultrasound or indistinguishable from concurrent benign prostatic hyperplasia. Diagnosis therefore rests on prostate biopsy. Biopsies are not simply directed at ultrasonically visible lesions, as these would miss many cancers; rather the whole gland is sampled. The sampling itself is systematic, using patterns based on prostate zonal anatomy and the geographical distribution and frequency of cancer. This review explains the evolution of the prostate biopsy technique, from the classical sextant biopsy method to the more recent extended biopsy protocols (8, 10, 12, >12 and saturation biopsy protocols). Extended protocols are increasingly being used to improve diagnostic accuracy, especially in those patients who require repeat biopsy. This trend has been facilitated by the ongoing improvement in safety and acceptability of the procedure, particularly with the use of antibiotic prophylaxis and local anaesthesia. The technical details of these extended protocols are discussed, as are the current data regarding procedure-related morbidity and how this may be minimized.
Collapse
Affiliation(s)
- J Raja
- Department of Radiology, St George's Hospital, Tooting, London, UK.
| | | | | | | |
Collapse
|
19
|
Correct answers to multiple choice questions appearing in the European Urology Update Series 2005. BJU Int 2005. [DOI: 10.1111/j.1464-410x.2005.05978.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
20
|
Dutta Roy S, Philip J, Javle P. THIS ARTICLE HAS BEEN RETRACTED Trends in prostate cancer incidence and survival in various socioeconomic classes: A population-based study. Int J Urol 2005; 12:644-53. [PMID: 16045557 DOI: 10.1111/j.1442-2042.2005.01111.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVES Prostate cancer is currently the commonest cancer in men of all ages in UK, but robust demographic data of its distribution in various socioeconomic classes is lacking. We aimed to analyze its incidence, mortality and survival trends in West Midlands, England, from 1986 to 2000 in terms of socioeconomic deprivation. METHODS Data were collated from the regional cancer registry database and a well-validated demographic score, the Townsend band, was employed as an indicator of social deprivation, including four variables as proxy indicators of socioeconomic status. Individual cases were allocated to one of five deprivation categories using postcode at diagnosis. Regression trend analysis at 1 and 5 years was performed and a P-value derived from the t-test statistic. RESULTS In the mid-1980s, the incidence rate ratio in affluent:deprived classes was 0.9, with age-standardized rates of 35.23 and 39.53 per 100 000 people. This ratio increased to 1.5 by 2000 with age-standardized rates of 95.98 and 63.13, respectively (172% increase in affluent compared with 60% in deprived). The affluent groups had a 7 and 13% survival advantage at 1 and 5 years; the survival advantage at 1 year was statistically significant (P=0.03). CONCLUSIONS The preferential changes in incidence and survival in the affluent social classes are likely to be due to heightened awareness, resulting in increased prostate-specific antigen testing, which captures early and relatively slow-growing tumors with a better overall prognosis. If these bipolar trends are allowed to persist, then the gap between the affluent and deprived will continue to widen.
Collapse
Affiliation(s)
- Subhajit Dutta Roy
- Research Unit, Department of Surgery, Leighton Hospital, South Cheshire, UK.
| | | | | |
Collapse
|
21
|
Brett J, Watson E, Hewitson P, Bukach C, Edwards A, Elwyn G, Austoker J. PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK. BMC FAMILY PRACTICE 2005; 6:24. [PMID: 15946386 PMCID: PMC1180431 DOI: 10.1186/1471-2296-6-24] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 09/29/2004] [Accepted: 06/09/2005] [Indexed: 11/10/2022]
Abstract
BACKGROUND The role of Prostate Specific Antigen (PSA) testing in the early detection of prostate cancer is controversial. Current UK policy stipulates that any man who wishes to have a PSA test should have access to the test, provided he has been given full information about the benefits and limitations of testing. This study aimed to determine UK GPs' current reported practice regarding PSA testing, and their views towards informed decision-making and PSA testing. METHOD Online questionnaire survey, with a sample of 421 GPs randomly selected from a database of GPs across the UK. RESULTS 95% (400/421) of GPs responded. 76% of GPs reported having performed a PSA test for an asymptomatic man at least once in the previous three months, with 13% reported having tested more than five men in this period. A majority of GPs reported they would do a PSA test for men presenting with a family history and requesting a test, for asymptomatic men requesting a test and also for men presenting with lower urinary tract symptoms. Reported testing rates were highest for men with a family history. Amongst men with lower urinary tract symptoms and men with no symptoms, reported testing rates were significantly higher for older than younger men. The majority of GPs expressed support for the current policy (67%), and favoured both the general practitioner and the man being involved in the decision making process (83%). 90% of GPs indicated that they would discuss the benefits and limitation of testing with the man, with most (61%) preferring to ask the man to make a further appointment if he decides to be tested. CONCLUSION This study indicates that PSA testing in asymptomatic men is a regular occurrence in the UK, and that there is general support from GPs for the current policy of making PSA tests available to 'informed' men who are concerned about prostate cancer. While most GPs indicated they would discuss the benefits and limitations prior to PSA testing, and most GPs favoured a shared approach to decision making, it is not known to what extent men are actually being informed. Research is needed to evaluate the most effective approach to assisting men in making an informed decision about whether or not to have a PSA test.
Collapse
Affiliation(s)
- Jo Brett
- Cancer Research UK Primary Care Education Research Group, Department of Primary Health Care, Old Road Campus, University of Oxford, Headington, Oxford, OX3 7LF, UK
| | - Eila Watson
- Cancer Research UK Primary Care Education Research Group, Department of Primary Health Care, Old Road Campus, University of Oxford, Headington, Oxford, OX3 7LF, UK
| | - Paul Hewitson
- Cancer Research UK Primary Care Education Research Group, Department of Primary Health Care, Old Road Campus, University of Oxford, Headington, Oxford, OX3 7LF, UK
| | - Colleen Bukach
- Cancer Research UK Primary Care Education Research Group, Department of Primary Health Care, Old Road Campus, University of Oxford, Headington, Oxford, OX3 7LF, UK
| | - Adrian Edwards
- Centre for Health Sciences Research, Cardiff University, 56 Park Place, Cardiff, CF10 3AT, UK
| | - Glyn Elwyn
- Centre for Health Sciences Research, Cardiff University, 56 Park Place, Cardiff, CF10 3AT, UK
| | - Joan Austoker
- Cancer Research UK Primary Care Education Research Group, Department of Primary Health Care, Old Road Campus, University of Oxford, Headington, Oxford, OX3 7LF, UK
| |
Collapse
|
22
|
Chappell B, McLoughlin J. Technical considerations when obtaining and interpreting prostatic biopsies from men with suspicion of early prostate cancer: Part I. BJU Int 2005; 95:1135-40. [PMID: 15877722 DOI: 10.1111/j.1464-410x.2005.05538.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Barnaby Chappell
- Department of Urology, West Suffolk Hospital, Bury St Edmunds, Suffolk, UK
| | | |
Collapse
|
23
|
Postma R, Schröder FH. Screening for prostate cancer. Eur J Cancer 2005; 41:825-33. [PMID: 15808952 DOI: 10.1016/j.ejca.2004.12.029] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2004] [Accepted: 12/02/2004] [Indexed: 11/23/2022]
Abstract
Epidemiologically, prostate cancer is the most common cancer in the Western world after skin cancer. To date, it is still unknown whether screening for prostate cancer is justified, because results of randomised clinical trials are not yet available. The available screening tests (i.e. prostate-specific antigen (PSA) test) do not always detect cancers that otherwise would have resulted in prostate cancer mortality. Favourable results from prostate cancer screening include an increasing number of men with localised disease and an increase in the number of well-differentiated tumours. However, the risk of overdiagnosis and subsequent over-treatment (due to the diagnosis of localised disease), using aggressive therapies fuels arguments against screening. Therefore, until more evidence is available proving otherwise, prostate cancer screening can only be justified in the context of clinical trials.
Collapse
Affiliation(s)
- R Postma
- Department of Urology, Josephine Nefkens Institute, Erasmus MC, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.
| | | |
Collapse
|
24
|
Ruffion A, Manel A, Massoud W, Decaussin M, Berger N, Paparel P, Morel-Journel N, Lopez JG, Champetier D, Devonec M, Perrin P. Preservation of prostate during radical cystectomy: Evaluation of prevalence of prostate cancer associated with bladder cancer. Urology 2005; 65:703-7. [PMID: 15833512 DOI: 10.1016/j.urology.2004.10.076] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2004] [Revised: 10/10/2004] [Accepted: 10/29/2004] [Indexed: 11/20/2022]
Abstract
OBJECTIVES To estimate the frequency and characteristics of prostatic lesions discovered incidentally in radical cystoprostatectomy specimens and to determine whether any factors would allow for the detection of prostate cancer preoperatively. METHODS A total of 100 radical cystoprostatectomy specimens with orthotopic bladder reconstruction were performed for malignant bladder disease between 1990 and 2000. The mean patient age at surgery was 62 +/- 8 years (range 32 to 75). Digital rectal examination and prostate-specific antigen (PSA) assay were done routinely before surgery. During the 10-year study period, the same pathologist examined the prostatic tissues from radical cystoprostatectomy specimens using McNeal's technique on fine slices every 2.5 mm. RESULTS The overall incidence of prostate cancer discovered incidentally in radical cystoprostatectomy specimens was 51%, of which 29% were microcancers (volume less than 0.5 cm3) and 22% were significantly larger (volume 0.5 cm3 or more). The mean Gleason score was 6. Of the tumors, 24% could be considered "clinically nonsignificant" (less than 0.5 cm3 and Gleason score less than 7). The mean preoperative PSA level was 4.13 +/- 1.36 ng/mL. Of 66 patients with a PSA level of less than 4 ng/mL (mean PSA 1.5 +/- 0.8) and a normal digital rectal examination before surgery, 50% had prostate cancer, of which 69% were microcancers. CONCLUSIONS The prevalence of prostate cancer (51%) in our series is among the highest in published reports. Furthermore, our results stress that currently no factors are available to enable the detection of "clinically significant" prostate cancer preoperatively.
Collapse
Affiliation(s)
- A Ruffion
- Urologie Lyon Sud, Centre Hospitalier Lyon Sud, Pierre Bénite, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Walsh K, O'Brien T, Salemmi A, Popert R. A randomised trial of periprostatic local anaesthetic for transrectal biopsy. Prostate Cancer Prostatic Dis 2004; 6:242-4. [PMID: 12970729 DOI: 10.1038/sj.pcan.4500662] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Increasingly transrectal ultrasound and biopsy is performed for the detection of prostate cancer. We have conducted a randomised trial to evaluate whether the addition of periprostatic local anaesthetic injection reduces the discomfort of the procedure. A total of 64 patients who attended a specialised prostate clinic and were being evaluated for an elevated prostate-specific antigen agreed to participate in the trial and were randomly allocated to two groups. The intervention group received 10 ml of 1% lignocaine in the periprostatic tissue prior to biopsy and the control group underwent a standard biopsy. All patients had a sextant biopsy under ultrasound guidance. After the procedure, they were asked to determine the severity of the pain on a scale of 0-10 and the whether the quality of the pain was mild, moderate or severe. The responses were distributed normally. The groups were compared using Student's t-test. Pain severity showed no significant difference between the two groups (P=0.14). There was a trend towards a statistical difference (P=0.07) on the qualitative pain scale. In conclusion, no significant difference in overall discomfort in men having sextant biopsies was detected between the two groups, suggesting that the administration of local anaesthetic may not be as valuable as early reports have suggested.
Collapse
Affiliation(s)
- K Walsh
- Department of Urology, Guys Hospital, London, UK.
| | | | | | | |
Collapse
|
26
|
Roobol MJ, Schröder FH. European Randomized Study of Screening for Prostate Cancer: achievements and presentation. BJU Int 2004; 92 Suppl 2:117-22. [PMID: 14983969 DOI: 10.1111/j.1464-410x.2003.4698x.x] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
27
|
Abstract
This article provides a review of present evidence that suggests that screening achieves a reduction in prostate cancer mortality. Aspects of quality of life and cost effectiveness are reviewed, as well as present test performance. The questions addressed in this article include the following: Is screening in its present form acceptable as a public health instrument? What changes are needed to improve the screening procedure? What are the research priorities in this field, assuming that the present evidence of prostate cancer mortality reduction is eventually confirmed by ongoing randomized controlled trials?
Collapse
Affiliation(s)
- Fritz H Schröder
- Department of Urology, Erasmus University MC, Academic Hospital Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
| |
Collapse
|
28
|
Kehinde EO, Sheikh M, Mojimoniyi OA, Francis I, Anim JT, Nkansa-Dwamena D, Al-Awadi KA. High serum prostate-specific antigen levels in the absence of prostate cancer in Middle-Eastern men: the clinician's dilemma. BJU Int 2003; 91:618-22. [PMID: 12699471 DOI: 10.1046/j.1464-410x.2003.04199.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To investigate the common causes of total serum prostate-specific antigen (PSA) values of> 10 ng/mL in an Arab population, as in the USA and Europe the risk of prostate cancer is considered high in men with such PSA levels. PATIENTS AND METHODS Serum total PSA was measured in men presenting to our hospital as part of the investigation for prostate cancer screening and/or in elderly men with prostatism. Men with a serum PSA level of> 10 ng/mL were further investigated by transrectal ultrasonography (TRUS) of the prostate and biopsy of suspicious lesions for histological diagnosis. In addition, the percentage of free PSA, PSA velocity and PSA density were determined. All the patients included in this study were men of Arab origin residing in Kuwait. RESULTS In all, 1700 men (mean age 55.6 years, range 35-94) were assessed; of these, 161 had a serum PSA of> 10 ng/mL, attributable to benign prostatic hyperplasia (BPH) in 110 (68%), BPH with histological features of prostatitis in 33 (21%) and prostate cancer in 18 (11%). TRUS of the prostate in 143 of the 161 men with either BPH or BPH with prostatitis showed varying grades of intraprostatic calcifications in 22 (15%). Both PSA density and percentage free PSA did not contribute to determining the causes of total PSA levels of> 10 ng/mL. There was a progressive decline in PSA in all patients with BPH and prostatitis, except one who at re-biopsy had prostate cancer (T1N0M0, G1). CONCLUSION Total PSA values of> 10 ng/mL in Arab men may be a result of BPH, BPH with prostatitis or prostate cancer, in that order. A gradual decline in total PSA (decreased PSA velocity) with time to < 4 ng/mL often confirms the diagnosis of BPH with prostatitis. The percentage of free PSA and PSA density may not be helpful in diagnosing prostate cancer with certainty in these patients. Compared with Caucasians in the USA and Europe, BPH and BPH with prostatitis appear to be more frequent causes of serum PSA levels of> 10 ng/mL in Arab men.
Collapse
Affiliation(s)
- E O Kehinde
- Department of Surgery, Mubarak Hospital & Faculty of Medicine, Kuwait University, Safat.
| | | | | | | | | | | | | |
Collapse
|
29
|
Abstract
Epidemiologically, screening is justified by the importance of the disease and the lack of prospects for primary prevention, but evidence from natural history is unhelpful since men are more likely to die with, rather than from, prostate cancer. The available screening tests do not always detect men whose lesions could result in future morbidity or mortality. Evidence is limited for the benefits of treatment for localised cancers detected through screening, whereas the evidence for harm is clear. Observational evidence for the effect of population screening programmes is mixed, with no clear association between intensity of screening and reduced prostate cancer mortality. Screening for prostate cancer cannot be justified in low-risk populations, but the balance of benefit and harm will be more favourable after risk stratification. Prostate cancer screening can be justified only in research programmes designed to assess its effectiveness and help identify the groups who may benefit.
Collapse
|
30
|
|
31
|
|
32
|
Parkinson MC, Bott SRJ, Montironi R, Melia J. Screening for prostatic cancer and its evolution within Britain. J Pathol 2002; 197:139-42. [PMID: 12015735 DOI: 10.1002/path.1088] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
The arguments for and against screening for prostatic cancer are frequently discussed (Albertsen PC. Screening for prostate cancer is neither appropriate nor cost-effective. Urol Clin North Am 1996; 23: 521-530; Schroder FH, Alexander FE, Bangma CH, Hugosson J, Smith DS. Screening and early detection of prostate cancer. Prostate 2000; 44: 255-263). In contrast, this paper outlines how screening became possible, why the decision was made not to initiate a national screening programme in Britain, the other pathways being pursued, and the current problems, in particular the issue of histopathology workload.
Collapse
|
33
|
Gómez De Vicente JM, Luján Galán M, Páez Borda A, Romero Cagigal I, Moreno Santurino A, Santos Arrontes D, Berenguer Sánchez A. [Detection of prostatic cancer in the PSA range between 3 and 3.9 ng/ml]. Actas Urol Esp 2002; 26:271-4. [PMID: 12090185 DOI: 10.1016/s0210-4806(02)72772-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
OBJECTIVE In our study, we analyze the benefit of lowering the PSA cutoff point for which a prostate biopsy is indicated from 4 to 3 ng/ml. MATERIALS AND METHODS We have considered 4.278 individuals coming from a prostate cancer screening program. We studied 1.217 interventions in which PSA was determined, indicating the prostate biopsy with PSA > or = 3 ng/ml. Digital rectal examination was never the indication for the biopsy. All biopsies were sextant and assisted by transrectal ultrasound. We compared the performance of the biopsy using 4 and 3 ng/ml as cut points. RESULTS Of the 1.217 interventions performed, 947 had PSA values lower than 3 ng/ml, 80 between 3 and 3.9 ng/ml and 190 over 4 ng/ml. A total of 189 patients (70% of these two last groups) underwent a prostate biopsy. With 4 ng/ml as the cut point, 134 biopsies were indicated, detecting 28 cancers (positive predictive value 20.9%). However 189 biopsies were indicated and 34 cancers detected by lowering the cut point to 3 ng/ml (positive predictive value 17.9%). The reduction in the biopsy performance was not statistically significant (OR = 0.89). None of the 6 additional cancers detected was palpable or ecographically visible (T1c), all of them had a Gleason score under 7 and half of them could be considered clinically relevant. CONCLUSIONS Lowering PSA cutoff point from 4 to 3 ng/ml improved the detection rate in 21.4% not jeopardizing the biopsy performance. Therefore we think that the group of patients with PSA between 3 and 3.9 ng/ml as candidates for prostate biopsy, should be included in screening programs.
Collapse
|